Efficacy and safety of the novel α4β2neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

✍ Scribed by George Apostol; Walid Abi-Saab; Christopher J. Kratochvil; Lenard A. Adler; Weining Z. Robieson; Laura M. Gault; Yili L. Pritchett; David Feifel; Michelle A. Collins; Mario D. Saltarelli

• Publisher: Springer
• Year: 2011
• Tongue: English
• Weight: 321 KB
• Volume: 219
• Category: Article
• ISSN: 0033-3158
• DOI: 10.1007/s00213-011-2393-2